Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer
Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer
Breast Cancer
DRUG: Albumin-bound paclitaxel plus capecitabine|DRUG: capecitabine
PFS, Progression Free Survival, approximately 6 weeks
ORR, Objective Response Rate, approximately 6 weeks|OS, Overall Survival, Up to approximately 30 months
A Phase II, single-center, randomized study of albumin-bound paclitaxel combination with capecitabine versus capecitabine monotherapy in paclitaxel/docetaxel-resistant advanced breast cancer.